Renal cell carcinoma Pathways Pilot [ID6186]

  • In development
  • GID-TA11186
  • Expected publication date: TBC
Please note that belzutifan will not be included in the renal cell carcinoma pathways evaluation at this time. NICE and the company are continuing to liaise about scheduling for this topic and further participation in the pathway evaluations.